Galecto Inc
GLTO25.260USD
+2.630+11.62%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
33.53MCap. mercado
PérdidaP/E TTM
Más Datos de Galecto Inc Compañía
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Información de Galecto Inc
Símbolo de cotizaciónGLTO
Nombre de la empresaGalecto Inc
Fecha de salida a bolsaOct 29, 2020
Director ejecutivoSchambye (Hans T)
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 29
Dirección75 State Street
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02109
Teléfono14570705210
Sitio Webhttps://galecto.com/
Símbolo de cotizaciónGLTO
Fecha de salida a bolsaOct 29, 2020
Director ejecutivoSchambye (Hans T)
Ejecutivos de Galecto Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
--
-192.00%
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Otro
31.04%
Accionistas
Accionistas
Proporción
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Otro
31.04%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
32.16%
Hedge Fund
28.17%
Investment Advisor
17.71%
Corporation
15.10%
Venture Capital
1.85%
Research Firm
1.24%
Investment Advisor/Hedge Fund
0.67%
Otro
3.10%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
45
791.78K
49.64%
+565.88K
2025Q3
44
164.38K
12.40%
-149.96K
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ikarian Capital LLC
285.71K
17.91%
+285.71K
--
Nov 30, 2025
Fidelity Management & Research Company LLC
238.88K
14.98%
+238.88K
--
Nov 28, 2025
Point72 Asset Management, L.P.
100.00K
6.27%
+100.00K
--
Nov 12, 2025
Goldfischer (Carl S)
41.96K
2.63%
-1.00
-0.00%
Dec 01, 2025
Danmarks Eksport- og Investeringsfond
29.52K
1.85%
-29.52K
-50.00%
Sep 30, 2024
Connective Capital Management, LLC
26.96K
1.69%
+26.96K
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
